CDK7 Inhibitor Compounds Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective inhibitors for CDK7 is challenging due to its sequence and structure similarity with other CDKs, making it difficult to target specifically for treating proliferative diseases like cancer without affecting other kinases.
Innovation Solution
Design and development of compounds of Formula I, II, and III, which demonstrate greater specificity for CDK7 over CDK2, CDK9, and CDK12, with structures that allow for selective inhibition of CDK7 activity in various diseases, including cancers and fibrotic diseases, by forming pharmaceutically acceptable salts, solvates, and isotopic forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective CDK7 inhibitors are developed, then specificity for CDK7 is improved, but difficulty in development increases due to sequence and structure similarity with other CDKs
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions (R1-R6) on the core heteroaryl pyrimidine structure. These localized chemical modifications at specific regions of the molecule create selective interactions with CDK7's unique binding pocket features, allowing discrimination from other CDKs despite overall structural similarities.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halogens, alkyl groups, heteroaryl groups), their positions, and their combinations on the core structure. This systematic parameter optimization enables fine-tuning of binding affinity and selectivity for CDK7 versus other CDKs, resolving the selectivity challenge.
2Adaptability or versatility
If broad kinase inhibition is achieved, then therapeutic application range is improved, but selectivity for CDK7 deteriorates
Solution Approach 1:
The patent segments the kinase inhibition problem by designing a core heteroaryl pyrimidine structure with specific substituent positions (R1-R6) that can be independently optimized. This segmentation allows one region to provide broad kinase interaction while other regions provide CDK7-specific recognition, achieving both broad applicability and high selectivity simultaneously.
Solution Approach 2:
The core heteroaryl pyrimidine structure serves as a universal scaffold that can interact with multiple kinase families, providing broad therapeutic applicability. Meanwhile, the specific substituent patterns on this universal scaffold provide CDK7-specific recognition, enabling the molecule to perform multiple functions: broad kinase binding and selective CDK7 inhibition.
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).